Dr. Yanyan Lou

Professor/Associate Director of Early Cancer Theraputics/Thoracic Medical Oncologist at Mayo Clinic FL/ Wife and Proud Mom of 2/ Tweets are my own.

[Stephen V Liu, MD @StephenVLiu]

#ESMO23 Dr. @DoctorJSpicer presents OS data from KEYNOTE 671: neoadjuvant pembrolizumab + chemotherapy followed by surgery and adjuvant pembro x 1 year. Perioperative IO improves survival. OS HR 0.72, 3y OS rate 71% vs 64%, impressive tails. Now an FDA approved standard.

[Dr. Yanyan Lou @DrYanyanLou]

@OncoAlert @myESMO newly released and long waited ATTLAS results at ESMO, ABCP treatment improves PFS in EGFR or ALK NSCLC after TKI.

[Dr. Yanyan Lou @DrYanyanLou]

📣‼️🚨
FREE LIVE "Cancer Education Symposium" for #Patients with #LungCancer & #CareGivers (In-Person & Livestream/Online) on Saturday Nov 18th @MayoCancerCare @MayoClinic Florida:

#LungCancer 2023: AN ERA OF HOPE

PLEAZE SHARE
#LCSM

[Rami Manochakian MD, FASCO @RManochakian]

📣‼️🚨
FREE LIVE "Cancer Education Symposium" for #Patients with #LungCancer & #CareGivers (In-Person & Livestream/Online) on Saturday Nov 18th @MayoCancerCare @MayoClinic Florida:

#LungCancer 2023: AN ERA OF HOPE

PLEAZE SHARE
#LCSM

Registration link⬇️
https://t.co/QGO3uOJFs9

[Dr. Yanyan Lou @DrYanyanLou]

@OncoAlert, newly released and long awaited results at 2023 ESMO # lung cancer # EGFR # ALK, improved PFS with quadruple treatment regimen in EGFR or ALK NSCLC after TKI.

[Rami Manochakian MD, FASCO @RManochakian]

📣‼️🚨
FREE LIVE "Cancer Education Symposium" for #Patients with #LungCancer & #CareGivers (In-Person & Livestream/Online) on Saturday Nov 18th @MayoCancerCare @MayoClinic Florida:

#LungCancer 2023: AN ERA OF HOPE

PLEAZE SHARE
#LCSM

Registration link⬇️
https://t.co/QGO3uOJFs9

[Dr Riyaz Shah @DrRiyazShah]

MARIPOSA: really interesting ami-laz HR 0.7 over osi for PFS. Medians 26m vs 17m. RR similar. Cannot wait to see the curves next week. #ESMO23

[Dr. Yanyan Lou @DrYanyanLou]

Proud to be part of the study team making the new FDA approval: more choices for our NSCLC patients! Neoadjuvant/ adjuvant pembrolizumab for resectable non-small cell lung cancer https://t.co/1WvIyi0xvt

[Dr. Antonio Calles 🫁🚭 @Tony_Calles]

💥Merck Announces Pivotal KEYNOTE-671 Trial Meets Dual Primary Endpoint of Overall Survival (OS) in Resectable Stage II, IIIA or IIIB Non-Small Cell Lung Cancer (NSCLC) https://t.co/WuTCUbZlQA

[Dave Bjork @bjork5]

#lcsm #lungcancer

[Rami Manochakian MD, FASCO @RManochakian]

1/2 🔥🚨@OncoAlert Hot off the press

@FDAOncology approves the combination of #Encorafenib and #Binimetinib for #Patients with metastatic Non-Small cell #LungCancer with a #BRAF V600E mutation.

#LCSM #NSCLC
👇🏼
https://t.co/whEPWw5pO2

[Mayo Clinic @MayoClinic]

#PrecisionMedicineInitiative gearing up https://t.co/mbaXmnyF5H via @medpagetoday

[Dr. Yanyan Lou @DrYanyanLou]

PD-L1 positive patients have higher chance to response, but 10% PD-L1 negative patients also response, so no perfect biomarker yet.@MrPug94

[Dr. Yanyan Lou @DrYanyanLou]

ROVA-T Study open at Mayo soon! "Impressive Early Data for Rovalpituzumab Tesirine in Small Cell Lung Cancer" https://t.co/JLMLv6u3Nf

[Dr. Yanyan Lou @DrYanyanLou]

Move to front line! "First-Line Nivolumab Monotherapy Active in Advanced NSCLC" https://t.co/EMssBgr1Dm via @ascopost

[Dr. Yanyan Lou @DrYanyanLou]

Improved clinical activity, but more toxic # "First-Line Nivolumab With Platinum-Based Doublets in Advanced NSCLC"

[JTO & JTO CRR @JTOonline]

JTO Editor’s Choice: Lung Cancer in the Very Young: Treatment and Survival in the National Cancer Data Base. https://t.co/au5N3N3uf0 #lcsm

[Michael Fisch MD MPH @fischmd]

Overall response rate 28%, median PFS 3.6 mos, 24 wk PFS rate 41%, 12% halted due to adverse events https://t.co/75MeCa4ORd

[Dr. Yanyan Lou @DrYanyanLou]

"Dabrafenib Plus Trametinib Shows Activity in <em>BRAF</em> V600E–Mutant Metastatic NSCLC" https://t.co/JuCGrtIqc4 via @ascopost

[Dr. Yanyan Lou @DrYanyanLou]

"Sequential Nivolumab/Ipilimumab Appears More Active Than Reverse Sequence in Advanced Melanoma" https://t.co/JHLvd3k0hB via @ascopost

[Dr. Yanyan Lou @DrYanyanLou]

Bevacizumab for Early-Stage NSCLC" https://t.co/2oIoB0gdbW #oncology via @ascopost